IRX Share Price Performance
Recent IRX News & Updates
No updates
InhaleRx Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0057
- Gross Margin
- 100.00%
- Net Profit Margin
- -300.98%
- Debt/Equity Ratio
- -53.3%
InhaleRx Limited Competitors
About IRX
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
Australian Market Performance
- 7 Days: 0.2%
- 3 Months: 6.5%
- 1 Year: 7.3%
- Year to Date: 6.1%
The market has been flat in the last week, however the Materials sector is down 5.9%. As for the longer term, the market has risen 7.3% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading